Table of Contents

Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine
Dopamine Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine
Reuptake Inhibitor (SNRI) * Serotonin-2 Antagonists / Reuptake
Inhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor
(SPARI) * Serotonin Modulator and Stimulator (SMS) * Noradrenergic /
Specific Serotonergic Antidepressants (NaSSA) * Nonselective
Cyclic Antidepressants * Monoamine Oxidase Inhibitors * Reversible
Inhibitor of MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B)
Inhibitors (MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressants
on Neurotransmitters / Receptors * Pharmacological
Effects of Antidepressants on Neurotransmitters / Receptors *
Frequency of Adverse Reactions to Antidepressants at Therapeutic
Doses * Antidepressant Doses and Pharmacokinetics * Switching
Antidepressants * Antidepressant Augmentation Strategies
Electroconvulsive Therapy (ECT)
Bright Light Therapy (BLT)
Repetitive Transcranial Magnetic Stimulation (rTMS)
Antipsychotics
Second-Generation Antipsychotics / SGAs * Third-Generation
Antipsychotic / TGA * 5-HT21 Inverse Agonist Antipsychotic * First-
Generation Antipsychotics / FGAs * Effects of Antipsychotics on
Neurotransmitters / Receptors * Pharmacological Effects of Antipsychotics
on Neurotransmitters / Receptor Subtypes * Relative Tolerability
Profiles of Anti-psychotics * Frequency of Adverse Reactions
to Antipsychotics at Therapeutic Doses * Antipsychotic Doses and
Pharmacokinetics (Oral and Short-Acting Injections) * Comparison of
Long-Acting IM Antipsychotics * Switching Antipsychotics *
Antipsychotic Augmentation Strategies
Antipsychotic-Induced Extrapyramidal Side Effects and Their
Management
Extrapyramidal Adverse Effects of Antipsychotics * Treatment
Options for Extrapyramidal Side Effects * Effects on Extrapyramidal
Symptoms * Comparison of Agents for Treating Acute Extrapyramidal
Side Effects * Doses and Pharmacokinetics of Agents for Treating
Acute Extrapyramidal Side Effects
Anxiolytic (Antianxiety) Agents
Benzodiazepines * Comparison of the Benzodiazepines * Buspirone
Hypnotics / Sedatives
L-Tryptophan * Comparison of Hypnotics / Sedatives
Mood Stabilizers
Lithium * Anticonvulsants * Comparison of Anticonvulsants *
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic
Doses
Drugs for ADHD
Psychostimulants * Atomoxetine * Comparison of Drugs for ADHD *
2 Agonists * Augmentation Strategies in ADHD
Drugs for Treatment of Dementia
Cholinesterase Inhibitors * Memantine * Comparison of Drugs for
Treatment of Dementia
Sex-Drive Depressants
Comparison of Sex-Drive Depressants
Drugs of Abuse
Alcohol * Stimulants * Hallucinogens * Opioids * Inhalants / Aerosols
* Gamma-hydroxybutyrate (GHB) / Sodium Oxybate * Flunitrazepam
(Rohypnol) * Nicotine / Tobacco
Treatment of Substance Use Disorders
Acamprosate * Disulfiram * Naltrexone * Buprenorphine * Methadone *
Pharmacotherapy for Nicotine / Tobacco Use Disorder * Comparison
of Treatments for Nicotine / Tobacco Use Disorder
Unapproved Treatments of Psychiatric Disorders
Adrenergic Agents * Anti-Inflammatory Agents * Dopaminergic
Agents * GABA Agents / Anticonvulsants *
Hormones * NMDA Agents * 5-HT3 Antagonists * Miscellaneous
Natural Health Products
Pharmacogenomic Information for Common Psychotropic Drugs
Glossary
Drug Use in Pregnancy and Effects on Breast Milk
Patient Information Sheets
Appendix:
Neuroscience-Based Nomenclature
Index of Drugs

About the Author

Ric M. Procyshyn; BScPharm, MSc, PharmD, PhD; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada.
Kalyna Z. Bezchlibnyk-Butler; BScPharm, FCSHP; Toronto, ON, Canada.
J. Joel Jeffries; MB, FRCPC, DFCPA; Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada

Reviews

Previous praise for the Clinical Handbook: As a psychiatrist who routinely prescribes medications, I find this handbook invaluable. It is the most comprehensive book on this topic that I have come across.; Corey Goldstein, MD, Rush University Medical Center; A powerhouse of practical information ...Unrivalled in scope ... This outstanding and unique handbook is as rich in useful content as many full textbooks.; Barbara Jovaisas, PharmD, in Canadian Pharmacists Journal.; Comprehensive ... clearly organized ... an ideal resource for rapid and straight-forward retrieval of essential clinical information ...a `must have' for those who work in mental health care.; Marshall Cates, PharmD, in Annals of Pharmacotherapy.; Should be available at all nursing stations.; C. Lindsay DeVane, PharmD, in American Journal of Health Systems Pharmacy.; The handbook is easy to use, comprehensive in scope, and up to date - a winner!; Catherine Chiles, MD, in the Journal of Clinical Psychiatry; "This is the new edition of a very important book that provides valuable information which otherwise would be scattered among different publications. With the increasing rate of prescription of psychotropic drugs, this volume should be on the desk of every physician. The information is crucial for understanding side effects, vulnerabilities, and interactions of psychotropic drug treatment."; Giovanni A. Fava, MD, in Psychotherapy and Psychosomatics, September 2019